113 related articles for article (PubMed ID: 8973988)
1. Pharmacokinetics of a 7-day 17 beta-estradiol transdermal delivery system: effect of application site and repeated applications on serum concentrations of estradiol and estrone.
Boyd RA; Yang BB; Abel RB; Eldon MA; Sedman AJ; Forgue ST
J Clin Pharmacol; 1996 Nov; 36(11):998-1005. PubMed ID: 8973988
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women.
Boyd RA; Zegarac EA; Eldon MA; Sedman AJ; Forgue ST
Biopharm Drug Dispos; 1996 Aug; 17(6):459-70. PubMed ID: 8866037
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site.
Harrison LL; Harari D
J Clin Pharmacol; 2002 Oct; 42(10):1134-41. PubMed ID: 12362928
[TBL] [Abstract][Full Text] [Related]
5. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
6. The effect of site of application on the transcutaneous absorption of 17-beta estradiol from a transdermal delivery system (Climara).
Taggart W; Dandekar K; Ellman H; Notelovitz M
Menopause; 2000; 7(5):364-9. PubMed ID: 10993035
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
8. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Thebault JJ; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1997 Jul; 47(7):859-65. PubMed ID: 9272245
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
[TBL] [Abstract][Full Text] [Related]
12. Steady-state bioavailability of estradiol from two matrix transdermal delivery systems, Alora and Climara.
Buch A; Shen L; Kelly S; Sahota R; Brezovic C; Bixler C; Powell J
Menopause; 1998; 5(2):107-12. PubMed ID: 9689205
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
Guichard JP; Sauron R; Jones AB
J Clin Pharmacol; 1999 Aug; 39(8):811-6. PubMed ID: 10434233
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state.
Paoletti AM; Pilia I; Nannipieri F; Bigini C; Melis GB
Maturitas; 2001 Dec; 40(3):203-9. PubMed ID: 11731181
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol.
Scott RT; Ross B; Anderson C; Archer DF
Obstet Gynecol; 1991 May; 77(5):758-64. PubMed ID: 2014092
[TBL] [Abstract][Full Text] [Related]
18. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results.
Rohr UD; Saeger-Lorenz K
J Pharm Sci; 2002 Mar; 91(3):810-21. PubMed ID: 11920767
[TBL] [Abstract][Full Text] [Related]
19. Dose proportionality study of four doses of an estradiol transdermal system, Estradot.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Ibarra de Palacios P; Krinsky L
Maturitas; 2003 Nov; 46(3):173-85. PubMed ID: 14585520
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system.
Müller P; Botta L; Ezzet F
Eur J Clin Pharmacol; 1996; 51(3-4):327-30. PubMed ID: 9010707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
